PRINCETON, N.J., Nov. 15, 2017 /PRNewswire/ -- Promius Pharma LLC announced today that ZEMBRACE ® SymTouch ® (sumatriptan injection) 3 mg, an acute migraine headache treatment on the market since ...

Sumatriptan 5mg, 20mg; per spray. The vascular 5-HT 1 receptor subtype to which sumatriptan binds selectively, and through which it presumably exerts its antimigrainous effect, is present on cranial ...

Subcutaneous sumatriptan 6 mg is undeniably an excellent treatment of migraine. However, some patients have avoided using 6 mg sumatriptan because of unpleasant or unwanted side effects. To evaluate ...

Imitrex (sumatriptan) is a prescription drug that’s used to treat migraine with or without an aura. It’s not known whether Imitrex may be safe to use while pregnant or breastfeeding. If you can become ...

Par Pharmaceutical Companies, Inc. said today it will pay Spectrum Pharmaceuticals, Inc., $20 million for more profits from a collaboration to sell a copycat migraine drug.Par Pharmaceutical Companies ...

Imitrex is available as a generic drug. The maximum single recommended adult dose of Imitrex Injection for the acute treatment of migraine or cluster headache is 6 mg injected subcutaneously. For the ...

Dr. Reddy's Laboratories (NYSE: RDY), announced today that the U.S. Food and Drug Administration (FDA) has approved ZEMBRACE™SymTouch™ (sumatriptan succinate) injection, a drug-device combination ...

Tosymra (sumatriptan) is a prescription drug used to treat migraine. The drug comes as a nasal spray. You usually use a single dose, which may be repeated two more times in a 24-hour period if needed.

Tosymra Nasal Spray 10 mg is a Proprietary Acute Migraine Treatment Approved Under the 505(b)2 Pathway Based on Bioequivalence to Imitrex (sumatriptan) Injection 4 mg GlaxoSmithKline Recently Notified ...

Chatham-based Tonix Pharmaceuticals Holding Corp. and its wholly owned subsidiary Tonix Medicines Inc. announced June 26 that they entered into an agreement to acquire two fast-acting migraine ...

Nov 13 (Reuters) - Drugmaker Spectrum Pharmaceuticals Inc. on Monday said it settled a patent suit with GlaxoSmithKline relating to the UK-based company's migraine injection, Imitrex. Under the terms, ...